Markers and Immunoprofile of Myeloid Neoplasm

, Hans Guski2 and Glen Kristiansen3

Carl-Thiem-Klinikum, Institut für Pathologie, Cottbus, Germany

Vivantes Klinikum Neukölln, Institut für Pathologie, Berlin, Germany

Universität Bonn, UKB, Institut für Pathologie, Bonn, Germany


Diagnostic Antibody Panel for Myeloid Neoplasm

CD13, CD14, CD15, CD33, and MPO [1]

Myeloperoxidase (MPO)

Expression pattern: cytoplasmic

Main diagnostic use

Expression in other tumors

Expression in normal cells


Granulocytic sarcoma

Myeloid cells, monocytes

Positive control: bone marrow

Diagnostic Approach

Myeloperoxidase (MPO) is a heme protein and one of the main lysosomal enzymes in myeloid cells released during degranulation. MPO positivity is diagnostic for neoplasia of myeloid origin. MPO is constantly absent in normal and neoplastic lymphoid tissue.


CD15 is a further important marker for the myeloid lineage listed in details in the previous chapter. CD15 is expressed on the majority of granulocytes and monocytes and relates neoplasms.


Expression pattern: membranous/cytoplasmic

Main diagnostic use

Expression in other tumors

Expression in normal cells

AML (M0-5), CML

B- and T-ALL, ALK+ anaplastic large cell lymphoma

Monocytes, premyelocytes, myeloid blasts, dendritic cells, mast cells

Positive control

Diagnostic Approach

CD33 is a transmembrane glycoprotein involved in cell-to-cell adhesion. CD33 is expressed in the early myeloid progenitor cells after CD34 but absent in stem cells [2]. The expression of CD33 persists during myelomonocytic differentiation and is weakly detectable on granulocytes, monocytes, mast cells, and dendritic cells. CD33 is an important marker for most types of acute myeloid leukemia (M0–M5) (Fig. 17.1), chronic myeloid leukemia (CML), and granulocytic sarcoma in addition to chronic myelomonocytic leukemia.
Dec 25, 2017 | Posted by in ONCOLOGY | Comments Off on Markers and Immunoprofile of Myeloid Neoplasm

Full access? Get Clinical Tree

Get Clinical Tree app for offline access